Investigating how a protein affects inflammatory signaling in autoimmune diseases
Determining role of 14-3-3zeta in IL-17A signaling
This study is looking at a protein called 14-3-3zeta to see how it affects a signaling process related to IL-17A, which plays a role in autoimmune diseases like Inflammatory Arthritis, with the hope of finding new ways to help people with these conditions feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-11328229 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a protein called 14-3-3zeta in the signaling pathway of Interleukin-17A (IL-17A), which is known to contribute to autoimmune diseases like Inflammatory Arthritis. By studying how this protein interacts with other signaling molecules, the research aims to uncover mechanisms that could lead to new treatment strategies. The approach involves using animal models to observe the effects of manipulating this protein on disease progression and inflammation. The ultimate goal is to provide insights that could help in developing therapies for patients suffering from autoimmune conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with autoimmune diseases, particularly those experiencing symptoms of Inflammatory Arthritis.
Not a fit: Patients with non-autoimmune conditions or those who do not have inflammatory arthritis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating autoimmune diseases, potentially improving the quality of life for affected patients.
How similar studies have performed: Previous research has shown promising results in understanding similar signaling pathways in autoimmune diseases, indicating that this approach could yield valuable insights.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Chakravarti, Ritu — University of Kentucky
- Study coordinator: Chakravarti, Ritu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.